Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, has recently undergone significant changes in its market position ...

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

Nevro Corp has been recognized for its differentiated high-frequency SCS offerings and solid sales base. However, the company has faced challenges in recent years, struggling with market share and ...

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system in select European countries in January 2025 following the receipt of CE Mark Certification in November 2024.

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions ...